Increased blood creatinine level due to CDK 4/6 inhibitor treatments: Single center experience

Combinations of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6) (ribociclib, palbociclib, abemaciclib) and endocrine therapy (ET) are the first-line recommended treatment in patients with hormone receptor (HR)-positive HER2-negative metastatic breast cancer, unless there is visceral crisis due to organ metastases.We aimed to report the increase in creatinine levels in our patients who developed due to ribociclib and palbociclib use, which were not reported among the common side effects of CDK 4/6 inhibitor treatment and because there was no report in the literature.